Tenaya Therapeutics Inc (TNYA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.68-1.74%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TNYA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on progressing TN-201 and TN-401 through clinical trials with interim data releases and regulatory engagement for late-stage pivotal trial planning.
Stated as a priority in 2 of last 2 quarters. Management reported sharing new safety and efficacy data for TN-201 and TN-401 in 2026-Q2 and planned interim data releases in 2026-Q1. They are actively engaging with regulators on late-stage pivotal trial plans with updates expected in 2026-Q4. The trajectory shows delivering on clinical development milestones and regulatory engagement as committed.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We shared new safety and clinical benefit data for TN-201 and TN-401 and are engaging with regulators on pivotal trial plans.”
“We expect additional data from TN-201 and TN-401 to support registrational pathways and plan interim data reports in 2026.”
Progress TN-301 toward clinical trials with planned proof-of-activity Phase 2 trial initiation in second half of 2027.
Stated as a priority in 2 of last 2 quarters. Management reported ongoing enabling toxicology work and plans to initiate at least one proof-of-activity Phase 2 clinical trial for TN-301 in the second half of 2027. The trajectory is consistent with advancing the small molecule candidate toward clinical evaluation as planned.
“TN-301 advancing toward Phase 2 trial start in second half of 2027; toxicology work ongoing.”
“TN-301 development plans include advancing toward clinical trials to generate proof-of-activity data.”
Manage cash and expenses prudently to fund operations through Q3 2027, supported by collaboration payments and cost savings.
Stated as a priority in 4 of last 4 quarters. Cash and cash equivalents were $80.9M in 2026-Q1 and $78.1M in 2026-Q2, including a $10M upfront payment from the Alnylam collaboration. Management expects these resources to fund operations through Q3 2027. The trajectory shows disciplined capital management and extension of the cash runway as committed.
“Cash of $78.1M including $10M upfront payment; sufficient to fund operations through Q3 2027.”
“Cash and equivalents $80.9M; resources plus $10M upfront from Alnylam expected to fund operations into second half of 2027.”
“Resources plus expected upfront payment from Alnylam sufficient to fund planned operations into second half of 2027.”
“Cost savings from prior spending reductions expected to support operations into second half of 2026.”
Lower operating expenses by decommissioning the Genetic Medicines Manufacturing Center and terminating its lease to reduce fixed costs.
Stated as a priority in 2 of last 2 quarters. The company decommissioned its GMMC facility in 2025 and entered a lease termination agreement in 2026-Q2, incurring a $21.8M impairment loss. This reflects active cost reduction efforts via facility consolidation and lease termination, consistent with management's stated priority.
“Entered Lease Termination Agreement for GMMC facility decommissioned in 2025 to reduce costs.”
“Company decommissioned GMMC facility in 2025 to reduce costs and plans to work with contract manufacturers.”
Appoint Eric Hyllengren as CFO to oversee financial strategy, capital allocation, and corporate development.
Newly stated in 2026-Q2. The company appointed Eric Hyllengren as CFO effective July 13, 2026, to lead financial strategy and capital allocation. This is a recent leadership change with no prior quarters stating this priority.
Over the trailing year it converted 0.86x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
16 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.